Fresno Practice Adopted New Glaucoma Implant
Eye-Q Vision Care has begun offering a continuous-release implant for patients with glaucoma and ocular hypertension.
Updated on Oct. 14, 2026 in Healthcare
Live Poll
Do you trust medical implants to manage chronic conditions more effectively than traditional self-administered treatments?
Eye-Q Vision Care in Fresno is now offering the FDA-approved iDose TR implant to patients with open-angle glaucoma and ocular hypertension. This device eliminates the requirement for daily prescription eye drops by continuously releasing medication directly into the eye.
Why it matters
The implant directly addresses patient barriers to adherence, such as arthritis and difficulty with self-administration, by replacing daily regimens with a three-year delivery mechanism. This shift has the potential to alter the long-term management model for chronic ocular conditions.
The iDose TR implant utilizes 75 mcg of travoprost to provide continuous medication release for a duration of three years. Clinical data indicates that 8 out of 10 patients remained drop-free one year after receiving the procedure.
The players
Eye-Q Vision Care
A Fresno-based provider of ophthalmological services and surgical vision care.
The details
The implant is surgically placed inside the eye, where it serves as an automated delivery system for travoprost. By removing the need for manual daily eye drop application, the device minimizes the risk of missed doses and challenges associated with physical dexterity. Practitioners should monitor for reported side effects, which include ocular pain, dryness, iris inflammation, and fluctuations in eye pressure.
Timeline
Three years is the duration of medication release from the implant.
Market Landscape
The introduction of the iDose TR implant marks a departure from reliance on daily, patient-administered topical medications. This transition aligns with broader industry trends toward long-acting, localized drug delivery systems designed to improve therapeutic adherence.
Operators in the healthcare sector should evaluate how such long-term implants affect patient throughput and recurring service models compared to traditional drop-based treatment plans. Management should consult with clinical staff regarding the billing and surgical requirements for this specialized device.
The takeaway
The adoption of continuous-release implants reflects a shift toward reducing patient-side burdens in chronic condition management. Owners should monitor how these technology shifts impact patient retention and service cycles for their clinical operations.
Further reading
For more details on local medical service trends, visit the Healthcare section.
More information
For more information on the practice and its services, visit the Eye-Q Vision Care information portal.
Source note: This article includes information reported by ABC30 Fresno.
Live Poll
Do you trust medical implants to manage chronic conditions more effectively than traditional self-administered treatments?
